Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

Endosense raises $36 million for TactiCath launch: European roll-out of Endosense's TactiCath force-sensing cardiac arrhythmia ablation catheter will be funded by a $36 million "Series B" private placement, announced Sept. 1. Proceeds also will be used for a U.S. clinical trial to support a PMA submission, according to the company. Headquartered in Geneva, Endosense received European CE mark approval in May for TactiCath treatment of supraventricular tachycardia of the right atrium. TactiCath "is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure," and it "has the potential to improve the effectiveness, safety and reproducibility" of treatment, according to Endosense. Founded in 2003, the firm estimates that the competitive, worldwide catheter ablation market is worth over $500 million annually. The financing round was led by Edmond de Rothschild Investment Partners

You may also be interested in...

St. Jude Gains Force-Sensing Catheter Technology With Endosense Acquisition

The $170 million acquisition, plus milestones, gives St. Jude Medical access to contact-force-sensing catheter ablation technology, strengthening its cardiac ablation pipeline and offering opportunities to enhance currently marketed products.

Neuronetics Overcomes Negative Panel Review To Earn Clearance For NeuroStar

FDA cleared Neuronetics' NeuroStar transcranial magnetic stimulation system for drug-resistant depression, despite a negative advisory panel review, based on a pivotal study subset analysis

Big Pharma CEOs Suggest Policy Changes As They Return To Beijing

Global CEOs of J&J, Pfizer, AbbVie and Takeda were among the top pharma executives attending the China Development Forum in its first in-person meeting in three years, and highlighted a number of pharma-related policy changes they would like to see in China. Meanwhile, a Japanese employee of Astellas has been detained in the country for alleged espionage.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts